^
Association details:
| Biomarker: | HER-2 exon 20G776>VC insertion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Exkivity (mobocertinib) (EGFR inhibitor, HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
MA11.02 Targeting HER2 Exon 20–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor, Mobocertinib
Published date:
08/18/2021
Excerpt:
Mobocertinib had the lowest HER2 exon 20 insertion IC50 / WT EGFR IC50 ratio of all three HER2 exon 20 insertion mutations compared with osimertinib, poziotinib, afatinib, neratinib, and pyrotinib, indicating that mobocertinib displayed the best selectivity profile in these models and could provide an improved efficacy and safety profile in clinic....HER2 exon 20G776>VC lung tumor had sustained complete response to mobocertinib
